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Ageing is an inevitable biological process that results in a progressive structural and
functional decline, as well as biochemical alterations that altogether lead to reduced
ability to adapt to environmental changes. As clock oscillations and clock-controlled
rhythms are not resilient to the aging process, aging of the circadian system may also
increase susceptibility to age-related pathologies such as Alzheimer’s disease (AD).
Besides the amyloid-beta protein (Aβ)-induced metabolic decline and neuronal toxicity
in AD, numerous studies have demonstrated that the disruption of sleep and circadian
rhythms is one of the common and earliest signs of the disease. In this study, we
addressed the questions of whether Aβ contributes to an abnormal molecular circadian
clock leading to a bioenergetic imbalance. For this purpose, we used different oscillator
cellular models: human skin fibroblasts, human glioma cells, as well as mouse primary
cortical and hippocampal neurons. We first evaluated the circadian period length, a
molecular clock property, in the presence of different Aβ species. We report here that
physiologically relevant Aβ1–42 concentrations ranging from 10 to 500 nM induced an
increase of the period length in human skin fibroblasts, human A172 glioma cells as
well as in mouse primary neurons whereas the reverse control peptide Aβ42-1, which
is devoid of toxic action, did not influence the circadian period length within the same
concentration range. To better understand the underlying mechanisms that are involved
in the Aβ-related alterations of the circadian clock, we examined the cellular metabolic
state in the human primary skin fibroblast model. Notably, under normal conditions,
ATP levels displayed circadian oscillations, which correspond to the respective circadian
pattern of mitochondrial respiration. In contrast, Aβ1–42 treatment provoked a strong
dampening in the metabolic oscillations of ATP levels as well as mitochondrial respiration
and in addition, induced an increased oxidized state. Overall, we gain here new insights
into the deleterious cycle involved in Aβ-induced decay of the circadian rhythms leading to
metabolic deficits, whichmay contribute to the failure in mitochondrial energymetabolism
associated with the pathogenesis of AD.
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INTRODUCTION
Ageing leads to a functional deterioration of many brain
systems, including the circadian clock, an internal time-
keeping system that generates ∼24-h rhythms in physiology
and behavior. Healthy as well as pathological brain aging
is associated with disturbances in both sleep-wake cycle and
circadian rhythms (Froy, 2011; Kondratova and Kondratov,
2012; Musiek and Holtzman, 2016). Age-related circadian
abnormalities have generally been considered as consequences
of neurodegenerative processes. However, it has been recently
implied that circadian disruptions can exacerbate the severity
of several age-related neurodegenerative pathologies. AD is
the most common neurodegenerative disorder among elderly
individuals. It accounts for up to 80% of all dementia cases
and ranks as the fourth leading cause of death among those
above 65 years of age. Multiple clinical studies have demonstrated
that the disruption of sleep and circadian rhythms is one of
the common and earliest signs of AD. Thus, abnormalities
in the circadian clock and in sleep quality worsen as the
disease progresses (Hofman and Swaab, 2006; Wulff et al.,
2010). Although this link between AD and circadian system
is increasingly evident, the underlying mechanisms are still
not well understood. Potential molecular mechanisms include
the circadian control of physiological processes such as brain
metabolism, amyloid-β (Aβ) metabolism, reactive oxygen species
(ROS) homeostasis, hormone secretion, autophagy, and stem
cell proliferation (Hastings et al., 2007; Kang et al., 2009; Lai
et al., 2012; Eckel-Mahan and Sassone-Corsi, 2013). However, it
remains mostly unclear if or how Aβ might lead to disruption
of the circadian clock which, in turn, could exacerbate the
neurodegenerative processes. As the underlying mechanisms of
AD onset are still unknown, it is worth considering the core
clock as a potential therapeutic target for the prevention of
neurodegeneration.
Although the exact molecular nature of AD pathogenesis
is still unclear and widely debated, a growing body of
evidence supports mitochondrial dysfunction as a prominent and
early, chronic oxidative stress-associated event that contributes
to synaptic abnormalities and ultimately, selective neuronal
degeneration in AD (Schmitt et al., 2012). The mitochondrial
energy deficiency is a fundamental characteristic of the AD
brain (Manczak et al., 2004) as well as of peripheral cells
derived from AD patients (Gibson et al., 1998). Since cellular
function relies heavily on this organelle, alterations to the
mitochondrial function have severe consequences on neuronal
activity and survival, which can, at least in part, contribute to the
development of AD.
It is essential to better understand the underlying molecular
mechanisms between the circadian network and the AD
pathology, particularly in regards to Aβ-related mitochondrial
alterations. In this study, we show evidence that Aβ (i) likely
contributes to the circadian clock disruption in AD at the
molecular level and (ii) impairs the circadian oscillations of the
mitochondrial activity with regard to oxygen consumption and
ATP generation. Our findings are consistent with the existence
of a crosstalk between the clock and the mitochondrial network
that maintains bioenergetic homeostasis in response to circadian
metabolic changes as well as with the Aβ-related mitochondrial
cascade hypothesis.
MATERIALS AND METHODS
Chemicals and Reagents
Dulbecco’s-modified Eagle medium (DMEM), RPMI-1640
medium, fetal calf serum (FCS), penicillin/streptomycin, NAD+,
NADH, dihydrorhodamine 123 (DHR), HBSS, MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and
PES (phenazine ethosulfate) were from Sigma-Aldrich (St. Louis,
MO, USA). Glutamax and DPBS were from Life Technologies
(Waltham, MA, USA). XF Cell Mitostress kit was from Seahorse
Bioscience (North Billerica, MA, USA). Horse serum (HS) was
from Amimed, Bioconcept (Allschwil, Switzerland).
Cell Culture and Synchronization of the
Circadian Rhythms
Isolated human skin fibroblasts from biopsies and glioma cell
line A172 (gift from Dr Steven A. Brown) were cultured in
DMEM/1% penicillin-streptomycin (v/v)/1% Glutamax (v/v)
[DMEM complete (DMEMc)]/20% heat-inactivated FBS (v/v)
(Pagani et al., 2011; Gaspar and Brown, 2015). Confluent
cells were infected using mice Bmal1::luciferase lentivirus and
were positively selected 3 days after infection. Mouse cortical
and hippocampal neurons were prepared from E15 embryos
according to the Swiss guidelines and were plated in poly-
l-lysine-coated plates according to the instruction of the
manufacturer (Lonza, Switzerland). After 7 days at 37◦C, 50% of
the medium was replaced with fresh medium every third day.
Prior to the assessment of circadian period length, cells were
synchronized for 15 min at 37◦C with 100 mM dexamethasone
as described previously (Pagani et al., 2011), while prior to the
measurement of nucleotide levels, mitochondrial reactive oxygen
species (mROS) and oxygen consumption rate (OCR) in human
primary fibroblast culture, serum shock treatment [DMEMc
supplemented with 50% heat-inactivated horse serum (v/v)] was
performed for 2 h at 37◦C to synchronize the cells accordingly
to a previously optimized method for these kind of experiments
(Cooper, 2003; Rosner et al., 2013). For measurements of
nucleotides levels and mitochondrial reactive oxygen species
(mROS) levels, experiments were performed starting from 12 h
post-synchronization time point and measured at 4 h intervals.
For measurements of oxygen consumption, experiments were
performed at 16 and 28 h post-shock.
Amyloid-Beta Peptide Preparation and
Treatment
The different amyloid-beta (Aβ) fragments [Aβ1–42; reverse
peptide (Aβ42−1); Aβ1–40; N-terminal fragment (Aβ1–28); C-
terminal fragment (Aβ34–42); shortest active peptide fragments
(Aβ25–35, Aβ15–25)] (Bachem, Bubendorf, Switzerland) were
rapidly dissolved in sterile PBS 1x, pH∼7.4 (stock concentration
500µM) and stored as aliquots at −80◦C until needed. One
day before treatment of cells with Aβ peptide fragments, 50µM
Aβ working solutions were prepared in PBS 1x, pH∼7.4. After
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securing the caps with parafilm, the tubes were incubated
on a table-top thermomixer (Eppendorf, Hamburg, Germany)
at 1,000 rpm (∼250 × g) at 37◦C for 24 h in order to
induce aggregation of the Aβ peptides into fibrils. For the
circadian period length determination, after synchronization
with dexamethasone (100 nM, 15 min at 37◦C), fibroblasts were
treated with 1, 10, 250, and 500 nM of Aβ in DMEM cell
culture medium containing 1% penicillin-streptomycin (v/v)/1%
Glutamax (v/v) (DMEMc)/10% FBS (v/v) for 5 days until
analyzed. This experimental setting requesting a rather long
incubation time over several days in aqueous medium, predicting
the formation of insoluble fibrillar Aβ aggegrates and fibrils,
did not allow to study the effects only of soluble Aβ species.
Therefore, also in the following assays, the same Aβ preparations
were used for the determination of nucleotides, ROS and
oxygen consumption rate to mimic corresponding conditions
of Aβ assembly and chronic toxicity. Thus, the cells were pre-
treated with 500 nM pre-aggregated Aβ (the most effective
concentration on bioenergetics readouts without cell death-
inducing properties) in DMEM cell culture medium containing
1% penicillin-streptomycin (v/v)/1% Glutamax (v/v) [DMEM
complete (DMEMc)]/20% heat-inactivated FBS (v/v) for 5 days.
After the synchronization, cells were treated again with 500 nM
Aβ in DMEM/1% penicillin-streptomycin (v/v)/1% Glutamax
(v/v) (DMEMc)/2% FBS (v/v) up to 48 h to maintain the Aβ
pressure on the synchronized cells.
Circadian Period Length Measurement
Human skin fibroblasts transfected with the lentiviral circadian
reporter mice Bmal1::luciferase (Brown et al., 2005; Gaspar and
Brown, 2015) were plated in single culture dishes (35× 10mm) at
a cell density sufficient to reach 70–80% of confluency on the start
day of recording of period length. After synchronization with
dexamethasone (100 nM, 15 min at 37◦C), cells were cultured
in DMEM supplemented with 10% heat-inactivated FBS, 10 mM
HEPES and 0.1 mM luciferin. For at least 5 days, the amount
of produced light that is proportional to Bmal1 gene expression
was measured using a Lumicycle instrument (Actimetrics). Data
were analyzed with Lumicycle Analysis software (LumicycleTM,
version 2.31, Actimetrics Software) and the period of oscillation
was calculated by least-mean-squares fitting of dampened sine
wave functions to the actual data as described previously (Pagani
et al., 2011).
Nucleotides Measurements
The total ATP content from synchronized human skin fibroblasts
was determined using a bioluminescence assay (ViaLighTM HT;
Cambrex Bio Science, Walkersville, MD USA) according to the
instruction of the manufacturer. Cells were plated in 8 replicates
into a 96-wells cell culture plate at a cell density sufficient to
reach 40–50% of confluency on the following day. The enzyme
luciferase, which catalyzes the formation of light from ATP and
luciferin was used. The emitted light is linearly related to the ATP
concentration and is measured using a multilabel plate reader
VictorX5 (Perkin Elmer).
To measure NAD+ and NADH, the two molecules were
separately extracted using an acid-base extraction method (HCL
0.1 mol/l–NAOH 0.1 mol/l). To determinate both NAD+ and
NADH, an assay was used that is based on passing the electron
from ethanol through reduced pyridine nucleotides to MTT [3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] in
a PES (phenazine ethosulfate)-coupled reaction resulting in the
formation of a purple precipitate (formazan) that, once dissolved,
can be quantified at 595 nm (VictorX5, Perkin Elmer).
Oxygen Consumption Rate (OCR)
The OCR was evaluated in synchronized fibroblasts as previously
described (Invernizzi et al., 2012). Briefly, human skin fibroblasts
were seeded at the density of 3 × 104 cells/100µl per well
on Seahorse Biosciences 24-well culture plates 1 day prior to
the serum-shock synchronization. On the next day, cells were
synchronized using serum shock (2 h at 37◦C). Afterwards, the
medium was exchanged to 500µl of assay medium [glucose-
free RPMI-1640 medium containing 2% FBS (v/v), 2 mM
sodium pyruvate, pH∼ 7.4]. Before to be placed in the Seahorse
XF24 Analyzer, the microplates were equilibrated in a CO2-free
incubator at 37◦C for 60 min. Then, the OCR allocated to basal
respiration at 16 and 28 h after synchronization were recorded in
real-time over 30 min.
Mitochondrial Reactive Oxygen Species
(mROS) Determination
Total level of mROS was assessed using the fluorescent dye
dihydrorhodamine 123 (DHR). Cells were plated in 8 replicates
into a black 96-wells cell culture plate at a cell density sufficient
to reach 40–50% of confluency on the day of the start of
mROS recording. After synchronization, cells were loaded at
the indicated time points with 10µM of DHR for 15 min
at room temperature in the dark on an orbital shaker. After
washing twice with HBSS, DHR, which is oxidized to cationic
rhodamine 123 that localizes within the mitochondria, exhibits
a green fluorescence that was detected using the multilabel plate
reader VictorX5 at 485 nm (excitation)/538 nm (emission). The
intensity of fluorescence was proportional to mROS levels in
mitochondria.
Statistical Analysis
Data were presented as mean ± S.D. Statistical analyses were
performed using the GraphPad Prism software. The curves
were generated by using a standard curve fit function in the
GraphPad Prism software. For statistical comparisons, One-way
ANOVA followed by Tukey’s multiple comparison test or Two-
way ANOVA followed by Bonferroni’s multiple comparison test
was used respectively. P < 0.05 were considered statistically
significant. Rhythmicity of ATP, NAD+, NADH, and mROS was
assessed using a non-parametric algorithm previously described
for determination of rhythmic transcripts (Hughes et al., 2010).
The JTK-cycle algorithm was used as implemented in R by
Kronauer as previously described (Dallmann et al., 2012). A
window of 24 h was used for the determination of circadian
periodicity and a P-value of< 0.05 was considered as statistically
significant.
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RESULTS
Aβ Disturbs Circadian Period Length
In vitro
To address the question whether Aβ is able to disturb the
circadian function, we first characterized the circadian period
length of synchronized fibroblasts in the presence of different
Aβ fragments (Figures 1A–C). For that purpose, we infected
cells with a circadian reporter construct (Bmal1 promoter-driven
expression of firefly luciferase-harboring lentivirus). First, the
effect of Aβ1–42, the major component of amyloid plaques in
AD brains that is more aggregation prone and exhibits higher
neurotoxicity than Aβ1–40, was investigated. Notably, cells had a
significantly longer period length in the presence of aggregated
Aβ1–42 at concentrations from 10 up to 500 nM compared to
controls (Figures 1A,B), while 1 nM was not yet effective. At a
concentration of 250 nM the maximum effect on prolongation
of period length was already reached. However, amplitude
(the difference between peak and nadir expression values) was
unchanged (data not shown). Notably, up to a concentration
of 500 nM, cell viability was not significantly impaired in
these experimental settings (data not shown). Consistent with
findings showing that the reverse control peptide Aβ42-1 is
inactive (Zhang et al., 2002), Aβ42-1 did not disturb the cellular
circadian properties. Similarly, Aβ1–42 treatment also induced
an increase in the period length in synchronized glioma A172
FIGURE 1 | Amyloid-β increases the circadian period length. (A) Representative luminescence records from human skin fibroblasts transfected with mice
Bmal1::luciferase reporter in presence of amyloid-β 1–42 (500 nM) or of the reverse peptide amyloid-β 42-1 (500 nM) compared to the condition in the absence of Aβ
species (CRTL). (B, C) Circadian period length determined in synchronized human skin fibroblasts transfected with mice Bmal1::luciferase reporter in presence of
amyloid-β 1–42 and 42-1 (B), 1–40, 1–24, 34–42, 25–35, 35-25, and 15–25 (C) compared to the condition in the absence of Aβ species (CRTL) (dashed line).
(D) Circadian period length determined in synchronized human glioma A172 cells transfected with Bmal1::luciferase reporter in presence of amyloid-β 1–42 compared
to control (CRTL) (dashed line). (E) Circadian period length determined in synchronized cortical primary mouse neurons transfected with Bmal1::luciferase reporter in
presence of amyloid-β 1–42 compared to control (CRTL) (dashed line). (F) Circadian period length determined in synchronized hippocampal primary mouse neurons
transfected with Bmal1::luciferase reporter in presence of amyloid-β 1–42 compared to control (CRTL) (dashed line). Bars represent the mean of at least three
independent experiments ± SD. **P < 0.01; ***P < 0.001 for Student’s two-tailed t-test, compared to control.
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cells as well as in cortical and hippocampal primary mouse
neurons (Figures 1D–F). In order to identify the specific Aβ
fragment/s responsible for the increase in the period length,
we then treated the synchronized fibroblasts with different Aβ
species (Aβ1–40, the most abundant Aβ isoform in the brain,
Aβ1–28, Aβ34–42, Aβ15–25, and Aβ25–35) within the same range
of concentrations (Figure 1C). Surprisingly, all the fragments
induced a significant alteration of the circadian function to a
similar extent as Aβ1–42 did itself. Together, these results suggest
that the aggregated nature of the Aβ species seem to represent an
important factor for the AD-related disruption of the circadian
rhythm.
Aβ Induces a Decline in the Circadian
Bioenergetic Homeostasis
Sincemitochondria were found to be a target of Aβ (Schmitt et al.,
2012), leading to mitochondrial dysfunction including a decline
in OxPhos and ultimately in ATP content, we investigated the
impact of Aβ on ATP content and on mitochondrial oxidative
metabolism with regard to rhythmic changes due to the the
tight relationship between the circadian clock and metabolism
(Brown, 2016; Panda, 2016). As ATP is primarily generated
via mitochondrial oxidative phosphorylation (OxPhos), we first
monitored whole cell ATP content as readout of OxPhos in
Aβ1–42-treated (500 nM) compared with untreated synchronized
human skin fibroblasts. Under normal conditions, total ATP
levels displayed a circadian rhythmicity in control cells (with
the peak at 16 h and the trough at 28 h), whereas ATP levels
in the Aβ-treated cells did not oscillate and were, in addition,
significantly reduced (Figure 2A).
We then monitored the real–time oxygen consumption rate
(OCR), an indicator of mitochondrial respiration in Aβ-treated
human skin fibroblasts compared to untreated cells at 16 h
corresponding to the ATP peak and at 28 h related to the
ATP trough using the Seahorse Bioscience XF24 Flux Analyzer
(Figure 2B). In untreated control cells, the OCR was significantly
decreased at the time point of the ATP trough (at 28 h) compared
to that of the ATP peak (at 16 h) (Figure 2B). Thus, the
circadian oscillations of OCR and ATP appear to be in the
same phase and fit well together in the way that at the time
point of high energy production, the oxidative phosphorylation
system provides the maximum performance. In contrast, Aβ1–42
treatment completely dampened the variation in the OCR and
no differences were found at 16 and 28 h after synchronization
(Figure 2B). Overall, these observations support the hypothesis
that circadian control of the mitochondrial function is strongly
disturbed by Aβ which may lead to a mitochondrial inability
to respond to an increasing metabolic demand. In addition,
we characterized the cellular bioenergetic profile of Aβ-treated
human skin fibroblasts compared to untreated cells, by mapping
OCR (basal respiration) vs. ATP for the indicated time points
(Figure 2C). Remarkably, untreated cells switched between a
metabolically active state corresponding to the high ATP (16 h)
and a metabolically resting state corresponding to low ATP levels
(28 h), while Aβ-treated cells remained in the metabolically
inactive state at both time points.
FIGURE 2 | Aβ induces a decline in circadian bioenergetic
homeostasis. (A) Total ATP levels from synchronized human skin fibroblasts
treated with Aβ 1–42 compared to non-treated cells (CTRL) measured at the
indicated time points (6 time points, n = 6 for each) (Two-way ANOVA; Aβ
effect: Df = 1, F = 3890, P < 0.0001; time effect: Df = 6, F = 34.25,
P < 0.0001; post hoc Bonferroni, ctrl vs. Aβ: at 16 h, t = 23.43,
***P < 0.0001, at 28 h, t = 11, ***P < 0.0001). Rhythmicity of ATP was
assessed using the JTK_Cycle algorithm as previously described (Dallmann
et al., 2012): JTK_Cycle, PCTRL = 2.07 × 10
−15, PAβ = 0.691. (B) Oxygen
Consumption Rate (OCR) was evaluated in Aβ-treated human skin fibroblasts
compared to untreated control cells at 16 and 28 h after synchronization,
respectively. (n = 11 replicates /group, three independent experiments)
(Two-way ANOVA, Aβ effect: Df = 1, F = 9.948, P = 0.0021; time effect: Df =
1, F = 44.08, P < 0.0001; post hoc Bonferroni, ctrl vs. Aβ: at 16 h, t = 5.886,
***P < 0.0001, at 28 h, t = 1.448, P > 0.05). (C) OCR/ATP: The basal OCR
corresponding to the ATP peak (at 16 h) and the ATP trough (at 28 h) are
plotted against the respective ATP content in control (white symbols) and Aβ
conditions (black symbols). Values represent the mean of each group (mean of
the ATP levels in abscissa/mean of the OCR in ordinate); n = 11–12
replicates/group of three independent experiments. The red arrows highlight
the Aβ-induced metabolic shift at 16 and 28 h after cell synchronization.
Alterations in Aβ-Related Mitochondrial
Functions Lead to Oxidative Stress
To further investigate the Aβ-induced imbalance in
mitochondrial homeostasis, we next evaluated the mitochondrial
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ROS levels as well as the NAD+/NADH ratio as oxidative
stress readout in synchronized human skin fibroblasts in the
presence or absence of Aβ (Figure 3). Again under normal
conditions, we found circadian oscillations for mitochondrial
ROS (mROS) levels exhibiting a peak at 16 h and a trough at
28 h after synchronization consistent with our findings on ATP
oscillations. Interestingly, Aβ1–42 (500 nM) increased globally
the mROS levels in the Aβ-treated cells, but it did not induce
a dampening of the circadian rhythmicity compared to the
untreated cells as found for bioenergetic readouts (Figure 3A).
In contrast, the NAD+/NADH ratio did not exhibit a circadian
pattern in control cells (Figure 3B). However, the ratio was
significantly augmented by Aβ1–42 treatment (about 10 times)
compared to untreated cells (Figure 3B). Together, our findings
suggest that Aβ triggers a decline of mitochondrial bioenergetics
including an abolishment of variations in ATP levels coupled to
a shift in the redox homeostasis toward a highly oxidized state.
DISCUSSION
In our study, we aimed to investigate, on the one hand,
whether Aβ can directly play a role in the molecular circadian
clock disturbances associated with AD and on the other hand,
whether Aβ impacts the integrity of the circadian regulation
of mitochondrial function, which could, in part, contribute to
the AD pathogenesis. The major findings were that, (i) AD-
related Aβ species are able to induce alterations in the molecular
circadian rhythms; (ii) Aβ provoked a drastic dysregulation in
the circadian control of the mitochondrial respiratory capacity
including reduced energy levels along with increased ROS
production.
Given that circadian rhythms become weaker and less
synchronized in specific regions of the brain (i.e., SCN) with
aging (Farajnia et al., 2012; Hastings and Goedert, 2013),
the progressive desynchrony likely promotes Aβ aggregation
contributing to the pathogenesis of AD. Comparable to human
studies (Weldemichael and Grossberg, 2010), it was shown for
several animal models of AD that they exhibit disturbances of
behavioral and physiological circadian rhythms (Musiek, 2015).
In mice, the circadian disturbances appear to correlate with the
degree of amyloid plaque burden and it has been suggested
that aggregated forms of Aβ might disrupt the circadian clock
(Sterniczuk et al., 2010; Roh et al., 2012). One proposed
explanation of circadian dysfunction in AD is the Aβ-related
impairment of the SCN caused by the drastic loss of vasopressin-
and vasoactive intestinal peptide-expressing neurons which are
essential in the maintenance of the SCN circadian function
(Swaab et al., 1985; Zhou et al., 1995; Farajnia et al., 2012).
Moreover, considerable evidence has emerged linking the
sleep-wake cycle with Aβ regulation in the brains of mice and
humans (Kang et al., 2009; Huang et al., 2012; Lim et al., 2014).
The diurnal variation of Aβ levels suggests that neuronal activities
related to the sleep/ wake cycle directly influence levels of Aβ
in the brain (Nir et al., 2011). Synaptic activity has been shown
to increase interstitial fluid Aβ release from neurons in both
mice and men (Cirrito et al., 2005; Brody et al., 2008). Similarly,
sleep deprivation increases plaque formation (Kang et al., 2009),
whereas enhanced sleep reduces Aβ deposition (Tabuchi et al.,
2015). The most active brain regions during quiet wakefulness
are located in the default mode network (DMN) and have been
reported as the first network affected by AD (Greicius et al., 2004)
exhibiting themost Aβ deposition during the development of AD
pathology (Mormino et al., 2011). Consistent with observations
of an alteration of circadian behavior in MCI and AD patients,
it can be speculated that the effects of Aβ protein on the
circadian period length can be related to disturbances in the
circadian rhythm and the sleep/wake cycle in MCI and early-
stage AD patients where a functional disruption of the SCN
is even observed in early disease stages. These age-associated
changes in the SCN have been proposed to be responsible for the
impairment of circadian clock synchronization throughout the
FIGURE 3 | Aβ induces a disruption in the cellular redox state. (A) Mitochondrial (mROS) reactive oxygen species levels were evaluated in synchronized human
skin fibroblasts treated with Aβ 1–42 compared to non-treated cells (CTRL) measured at the indicated time points (6 time points, n = 4 for each) (Two-way ANOVA; Aβ
effect: Df = 1, F = 859, P < 0.0001; time effect: Df = 6, F = 33.16, P < 0.0001; post hoc Bonferroni, ctrl vs. Aβ: at 16 h, t = 9.757, ***P < 0.0001, at 28 h, t =
9.035, ***P < 0.0001). Rhythmicity of mROS was assessed using the JTK_Cycle algorithm as previously described (Dallmann et al., 2012): JTK_Cycle,
P(CTRL)mROS = 5.40 × 10
−21, P(Aβ)mROS = 3.9 × 10
−18. (B) The NAD+/NADH ratio evaluated in in synchronized Aβ-treated human skin fibroblasts compared to
untreated control cells at the indicated time points. Values represent the mean ± SD; n = 9–12 replicates of three independents experiments (Two-way ANOVA; Aβ
effect: Df = 1, F = 408.7, P < 0.0001; time effect: Df = 6, F = 1.769, P = 0.1343).
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body causing circadian and sleep defects (Zhou et al., 1995; Stopa
et al., 1999).
Indeed, physiologically relevant concentrations of Aβ1–42,
which were not yet cytotoxic, were able to alter circadian
rhythms by increasing the period length in human fibroblasts,
human A172 glioma cells as well as in mouse primary neurons.
Unexpectedly, similar effects were detected with different
synthetic Aβ peptides including peptides lacking the N- and C-
terminus of the Aβ sequence (Aβ1–28, Aβ34–42, Aβ25–35, and
Aβ15–25). The whole amino-acids sequence of Aβ1–42 seems to be
involved in the disruption of the circadian rhythm (Mariani et al.,
2007), but already short Aβ fragments such as Aβ25–35 which
is processed in vivo by brain proteases (Clementi et al., 2005),
retain the effect of the full-length peptide on the period length
in our in vitro experiments, while Aβ fragments exhibiting the
reverse amino acid sequence were devoid of any action (Aβ42-1
and Aβ35–25). Unlike the reverse Aβ peptides, several peptide
fragments of Aβ, including our selection of Aβ species, form
aggregates in vitro which have a similar fibrillary morphology
in aqueous buffers (Serpell, 2000). Hence, the structure and the
assembly of the Aβ protein might be crucial for its mode of action
on circadian rhythmicity such as that of the period length.
Consistent with a growing body of evidence on the
circadian regulation of the mitochondrial function (Manella
and Asher, 2016), metabolic byproducts of mitochondrial
metabolism including ATP and mROS exhibited circadian
rhythmicity. Concurrent to the circadian rhythmicity in ATP
levels, mitochondrial oxygen consumption analyses showed
time-of-day-dependent variation in basal respiration (Isobe et al.,
2011; Peek et al., 2013). When in resting state (low ATP),
observed 28 h post-synchronization in cultured cells, the cells
exhibited a low respiration as well. The reverse was seen at 16
h post-synchronization, when the cells showed high ATP levels
and high respiration respectively. Thus, the circadian patterns of
OCR, ATP and mROS seem likely to be in the same phase and
fit well together in the way that at the time point of high energy
production the oxidative phosphorylation system provides the
maximum performance accordingly to the high energy demand,
initiating at the same time a maximum in mROS production due
to the high electron leakage from the electron transport chain.
Surprisingly, we did not observe a circadian rhythmicity of the
NAD+/NADH ratio, although it has been showed that this ratio
exhibited distinct circadian rhythms in ApoE−/− and C57BL/6J
SCN under the constant dark condition (Zhou et al., 2016). The
difference with our in vitro observations might be possibly due
to the fact that the SCN is a stronger clock than fibroblasts as
peripheral oscillators (Welsh et al., 2004).
Since disturbances in mitochondrial bioenergetics are known
as early and prominent features of AD-related neuronal
toxicity induced by Aβ (Yao et al., 2009; Garcia-Escudero
et al., 2013), we examined the potential impacts of Aβ on
the integrity of the mitochondrial function. Concomitantly,
defects in the mitochondrial function induced a decline in
mitochondrial metabolism including decreased mitochondrial
respiration, depletion in ATP content and increased oxidative
stress through increased mitochondrial ROS levels and drastic
changes in the NAD+/NADH ratio. Interestingly, only the
rhythmicity of ATP and OCR was entirely dampened in
the presence of Aβ. This Aβ-related loss of rhythmicity in
basal respiration and energy production could be explained
by altered expression patterns of the circadian clock genes
caused by an Aβ-induced post-translational degradation of the
circadian clock genes, Bmal1, and Per2 (Song et al., 2015),
thereby probably impairing the expression of clock-controlled
genes involved in the oxidative phosphorylation (Panda et al.,
2002). This impairment may, in turn lead to alterations of the
rhythmic assembly of mitochondrial supercomplexes to reach
their maximum performance in OXPHOS.Moreover, in addition
to the Aβ-related alterations in numerous enzymes essential
for the mitochondrial functions (Gibson et al., 1998), it has
been also recently proposed that the PERIOD proteins serve as
a rheostat for mitochondrial nutrient utilization by regulating
rate-limiting mitochondrial enzymes and therefore improving
mitochondrial metabolism (Neufeld-Cohen et al., 2016). Overall,
these observations suggest that Aβ likely induces alterations
in the molecular clock gene expression, which lead, in turn,
to changes in clock-controlled gene expressions and eventually
to disturbances in mitochondrial respiration and in energy
production.
Given the role of the circadian system in the regulation of ROS
homeostasis (Kondratova and Kondratov, 2012; Lee et al., 2013),
it is surprising that, while mROS levels increased drastically in
the presence of Aβ, they retained their circadian rhythmicity
despite the proposed Aβ-related alterations in the molecular
clock. Indeed, it has been described that ROS levels oscillated
in different mouse tissues and these rhythmic patterns were
disrupted in mice bearing impaired circadian clocks (Kondratov
et al., 2006). Our findings could be explained, at least in part, by
the fact that fibroblasts are known to have stronger antioxidant
defense mechanism than the brain (Cecchi et al., 2002). Other
explanations might be that the expression of clock-controlled
genes regulating the cellular antioxidant defense are less sensitive
to Aβ-induced insults than those of the OXPHOS or that the
antioxidant defense enzymes may act upstream of the electron
transport chain which is disturbed in its function by Aβ in this
way initiating and increasing oxidative stress. Further research
is needed to elucidate the underlying molecular mechanisms of
these cellular response systems. Our findings are in agreement
with previous observations from both animal models and AD
patients exhibiting mitochondrial failure as well as elevated
oxidative stress in their brains (Cecchi et al., 2002; Shi and
Gibson, 2007; Zhu et al., 2013).
In summary, we gained new insights into the Aβ-related
molecular circadian impairments in AD. Based on the complexity
of the multifactorial nature of AD, several vicious cycles are
interconnected within a larger vicious cycle where mitochondria
play a prominent role in the cascade of events leading to AD. All
of them, once set in motion, amplify their own processes, thus
accelerating the development of AD. One of these subordinate
cycles may represent the impact of a disrupted circadian
rhythm on mitochondrial function. Finally, the critical role of
mitochondria in the early pathogenesis of AD may make them
attractive as a preferential target for therapeutic strategies by
sustaining mitochondrial metabolic function. Since the diurnal
oscillations of Aβ levels in the brain appear to be closely related
to the sleep-wake cycle and Aβ, in turn, impacts the circadian
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regulation of mitochondrial functions, the possibility exists that
treating the aging-related sleep-wake impairments and upstream
events of the circadian dysfunction early, even prior to the
development of AD pathology, might prevent or slow down AD
pathogenesis pathways.
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